Crynodebau o Gyfarfodydd
E. Jódar, W. Polonsky, R. Réa, M. Warren, T. Vilsbøll, J. Håkan-Bloch, H. Vrazic, S. Lindberg, S.C. Bain. Semaglutide improves health-related quality of life vs placebo when added to standard-of care in patients with type 2 diabetes at high risk (SUSTAIN 6). 54th EASD Annual Meeting, 2018.
M.P. Gilbert, S.C. Bain, E. Franek, E. Jodar-Gimeno, M.A. Nauck, R.E. Pratley, R. Réa, J. Saraiva, S. Rasmussen, K. Tornøe, B. von Scholten, J. Buse, LEADER Publication Committee on behalf of the LEADER Trial Investigators. Effect of liraglutide on cardiovascular outcomes in elderly patients in the LEADER trial. 54th EASD Annual Meeting, 2018.
S. Madsbad, S.C. Bain, L. Chaykin, J. Lüdemann, J. Kjærulff Furberg, J. Rask Larsen, E. Yildirim, J. Rosenstock. Consistent HbA1c and body weight reduction with semaglutide independent of diabetes duration: SUSTAIN 1-5 and 7 patient-level meta-analysis. 54th EASD Annual Meeting, 2018.
L.A. Leiter, S. Verma, C.D. Mazer, S.C. Bain, J. Buse, S. Marso. M.A. Nauck, B. Zinman, H. Bosch-Traberg, H. Frimer-Larsen, M.M. Michelsen, D.L Bhatt. LEADER Publication Committee on behalf of the LEADER Trial Investigators. Liraglutide reduces cardiovascular events and mortality in type 2 diabetes independent of LDL cholesterol and statin use: results of the LEADER trial. 54th EASD Annual Meeting, 2018.
S.R. Chowdhury, S.F. Wong, R.L. Thomas, D.R. Owens, S.D. Luzio, G.J Dunseath. Incidence of diabetic retinopathy in newly diagnosed subjects with type 2 diabetes over 5 years: contribution of beta cell function. 54th EASD Annual Meeting, 2018.
R.L. Thomas, J.M. Rafferty, S.D. Luzio, D.R. Owens. Diabetic retinopathy in children and young people with type 1 diabetes in Wales. 54th EASD Annual Meeting, 2018
S.N. Parsons, S.D. Luzio, D.R. Owens, SMBG Study Group. Using structured self-monitoring of blood glucose to improve diabetes knowledge: the SMBG study. 54th EASD Annual Meeting, 2018
David R. Owens, Wolfgang Landgraf, Mei Zhang, Brian M. Frier, Luigi Meneghini, Philip Home, Geremia B. Bolli. High Levels of Baseline HbA1c, FPG, and 2-Hour Postprandial Glucose Are Key Predictors for Not Achieving HbA1c < 7.0% at Six Months in People with T2DM Starting Insulin Glargine 100 U/mL. American Diabetes Association 78th Scientific Sessions, 2018.
Alistair N. Lumb, Ian W. Gallen, Alex Bickerton, Ralph R. Abraham, Stephen C. Bain, Roy Harper, Robert E. Ryder, Abcd Nationwide Degludec Audit Contributors. Use of Insulin Degludec in Type 1 Diabetes Clinical Practice in the U.K.—General Practice Data from Two English Regions and Data from the Association of British Clinical Diabetologists (ABCD) Nationwide Degludec Audit. American Diabetes Association 78th Scientific Sessions, 2018.
Danny Sugimoto, Juan P. Frias, Didier Gouet, Róbert Takács, Ting Jia, Petra Örsy, Stephen C. Bain. Effects of IDegLira (Insulin Degludec/Liraglutide) in Patients with Poorly Controlled Type 2 Diabetes (T2D) with A1C >9%—Analyses from the DUAL Program. American Diabetes Association 78th Scientific Sessions, 2018.